List of Excipients in Branded Drug NIVESTYM

Nivestym Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Nivestym is Pfizer’s filgrastim-aafi biosimilar to Neupogen (filgrastim), approved by the FDA in 2018 for reducing the duration of neutropenia and related clinical complications in specified oncology, hematopoietic, and transplant settings. Its formulation uses a conventional protein-stabilization system based on sorbitol, polysorbate 80, acetate buffer, and water for injection. The main commercial opportunity is not a new excipient-led version of Nivestym. It is optimization of supply reliability, device presentation, cold-chain performance, hospital economics, and differentiated delivery formats within the constraints of an already approved biologic product [1, 2].

What excipients are used in Nivestym?

Nivestym contains filgrastim-aafi in an acidic, aqueous formulation. The FDA-approved formulation includes sodium acetate or acetate buffering components, polysorbate 80, sorbitol, water for injection, and pH-adjusting agents including acetic acid and sodium hydroxide. The product is supplied in single-dose prefilled syringes and single-dose vials at 300 micrograms per 0.5 mL and 480 micrograms per 0.8 mL strengths [1].

Formulation attribute	Nivestym profile
Active ingredient	Filgrastim-aafi
Reference product	Neupogen, filgrastim
Dosage form	Injectable solution
Strengths	300 mcg/0.5 mL; 480 mcg/0.8 mL
Primary stabilizing excipient	Sorbitol
Surfactant	Polysorbate 80
Buffer system	Acetate
Administration	Subcutaneous or intravenous, depending on indication
Storage	Refrigerated; protect from freezing and light
Product type	FDA-approved biosimilar
Regulatory listing	Purple Book biologic listing, not an Orange Book small-molecule listing

Sorbitol helps control protein stability and tonicity. Polysorbate 80 limits adsorption and interfacial stress during manufacturing, storage, and administration. The acetate system controls pH. Each excipient can affect aggregation, subvisible particles, oxidation, syringe compatibility, and immunogenicity risk.

How does Nivestym’s excipient system support product stability?

The Nivestym excipient system addresses the primary degradation pathways for recombinant granulocyte colony-stimulating factor proteins.

Protein aggregation and interfacial stress

Filgrastim is vulnerable to agitation, air-liquid interfaces, contact with container surfaces, and repeated handling. Polysorbate 80 reduces surface adsorption and agitation-induced aggregation. Its degradation products can create separate quality risks, including peroxide formation and potential protein oxidation. Control of polysorbate raw-material quality, peroxide levels, and storage conditions is therefore commercially relevant.

Freeze-thaw protection

Sorbitol provides tonicity and contributes to protection against some freeze-thaw stresses. Accidental freezing remains a material risk because frozen protein solutions can show aggregation or particle formation after thawing. Cold-chain controls, shipping validation, and pharmacy handling instructions are part of the commercial value proposition.

pH control

Acetate buffering maintains the acidic formulation environment required for product stability. Buffer concentration and pH can affect protein conformation, aggregation, syringe-material interaction, and injection tolerability. Any change to buffer composition would require comparability, stability, and regulatory justification.

Container compatibility

Nivestym is supplied in prefilled syringe and vial presentations. The formulation must remain compatible with elastomer closures, syringe components, needle systems, and container surfaces. Silicone oil, tungsten residues, adhesive components, and extractables from primary packaging can affect particulate levels and protein quality.

What formulation patents protect Nivestym?

Nivestym is a biologic product rather than a conventional small-molecule drug. Its primary legal protection is not determined through Orange Book patent listings. The relevant regulatory and intellectual-property records include the FDA Purple Book, Pfizer’s patent portfolio, process patents, formulation patents, manufacturing know-how, and biologic reference-product exclusivity rules [2, 3].

The core Neupogen composition and use patents have largely expired in the United States. Nivestym entered a market that already included Zarxio and other filgrastim products. Pfizer’s commercial protection therefore depends more heavily on regulatory approval, manufacturing scale, supply continuity, contracting, and product presentation than on a broad, blocking excipient patent.

A commercially useful excipient patent would need to claim a specific and defensible technical combination, such as:

• A defined filgrastim concentration with a narrowly specified acetate and sorbitol range.
• A polysorbate 80 concentration linked to reduced aggregation or oxidation.
• A formulation with improved stability under a defined temperature excursion.
• A low-particle formulation in a specified syringe or vial system.
• A container-closure combination that reduces adsorption or extractables.
• A lyophilized or concentrated presentation with demonstrated clinical or manufacturing advantages.
• A manufacturing process that limits polysorbate degradation or protein oxidation.

Broad claims covering filgrastim with sorbitol, acetate, or polysorbate 80 would face substantial novelty and obviousness pressure because these excipients are established in recombinant protein formulations.

When does Nivestym lose exclusivity?

Nivestym does not have a conventional small-molecule exclusivity clock comparable to a new chemical entity listed in the Orange Book. The reference product, Neupogen, received biologic reference-product exclusivity before Nivestym was approved. The FDA approved Nivestym in July 2018 under the biosimilar pathway created by the Biologics Price Competition and Innovation Act [1, 4].

Event	Date or status
Neupogen FDA approval	1991
First U.S. biosimilar filgrastim, Zarxio	Approved March 2015
Nivestym FDA approval	July 20, 2018
Nivestym U.S. commercial launch	2018
Biosimilar interchangeability status	Must be assessed separately from biosimilarity; original Nivestym approval was not an automatic substitution designation
Patent listing mechanism	Purple Book and patent-disclosure procedures, not ordinary Orange Book listing
Market exclusivity outlook	Primarily depends on product-level patents, manufacturing barriers, contracting, and supply economics

Nivestym does not receive a new 12-year reference-product exclusivity period. That period applies to the reference biologic, not to a biosimilar sponsor’s product. A competing filgrastim biosimilar can enter after satisfying the FDA’s statutory requirements and resolving any applicable patent issues.

What is the Orange Book and Purple Book status of Nivestym?

Nivestym is not treated like an ordinary tablet, capsule, or small-molecule injection for Orange Book purposes. It is a biologic approved under the 351(k) biosimilar pathway and is identified in the FDA Purple Book [2].

The Purple Book records biologic products, reference products, biosimilars, interchangeable biosimilars, and related exclusivity information. Patent disputes involving biosimilars are generally managed under the BPCIA patent-exchange framework and federal patent litigation rather than through the traditional Orange Book Paragraph IV process.

Do Nivestym competitors file Paragraph IV challenges?

The standard Orange Book Paragraph IV mechanism does not directly govern Nivestym because Nivestym is a biologic. A biosimilar competitor can still face patent litigation, but the legal pathway is different.

BPCIA patent disputes

The BPCIA creates a patent-information exchange process between a biosimilar applicant and the reference-product sponsor. Disputes can concern:

• Manufacturing methods.
• Cell culture and purification.
• Formulation.
• Delivery devices.
• Specific indications or methods of use.
• Packaging and combination-product components.

For a mature product such as filgrastim, the practical risk from fundamental composition patents is lower than for a recently launched biologic. Process patents and device patents can remain relevant, particularly where the applicant intends to use a different manufacturing platform or a prefilled syringe.

Nivestym-specific litigation exposure

Publicly available FDA materials do not identify Nivestym as being subject to a continuing, high-profile patent injunction that blocks ordinary U.S. supply. The absence of a blocking dispute does not eliminate freedom-to-operate risk for a new manufacturer. A proposed competitor would still need to assess Pfizer-related manufacturing, device, formulation, and use patents.

What excipient strategies could create commercial opportunities for Nivestym?

1. Polysorbate optimization

Polysorbate 80 is functional but can hydrolyze or oxidize over time. A commercial development program could evaluate:

• Lower-peroxide polysorbate grades.
• Alternative polysorbate 20 or nonionic surfactants.
• Surfactant concentration reduction.
• Antioxidant or metal-control strategies.
• Improved raw-material specifications.
• Alternative surfactant delivery during manufacturing.

Any substitution would require a complete analytical comparability package. The commercial value would be highest if the new system improved shelf life, reduced particles, or enabled less restrictive shipping conditions.

2. Surfactant-free or low-surfactant formulations

A lower-polysorbate formulation could reduce surfactant degradation and potentially improve long-term quality. The technical challenge is maintaining protection against adsorption and agitation-induced aggregation. This opportunity is more suitable for a next-generation filgrastim product than for a minor post-approval change to Nivestym.

3. Room-temperature excursion resistance

Hospitals and specialty pharmacies incur costs from refrigerated storage and temperature excursions. A formulation with validated stability during short, defined periods outside refrigeration could reduce product waste. The claim would need to be based on controlled stability data, not a general room-temperature label statement.

4. High-concentration or low-volume presentations

A higher-concentration formulation could reduce injection volume and support patient self-administration. It could also improve logistics by increasing doses per shipping carton. The development risks include viscosity, syringeability, local tolerability, aggregation, and device-function changes.

5. Prefilled syringe and autoinjector compatibility

Device-based differentiation may provide greater commercial value than a new excipient alone. Opportunities include:

• Low-dead-space syringes.
• Needle-safety systems.
• Autoinjector-compatible viscosity.
• Reduced injection-force systems.
• Human-factors improvements.
• Electronic dose tracking for specialty-pharmacy use.

A device change can create combination-product requirements and may require new human-factors, extractables, leachables, and container-closure studies.

6. Alternative dosage forms

Potential formats include a stabilized liquid for home administration, a lyophilized vial, or a concentrated formulation. A lyophilized product could improve stability but would add reconstitution steps and increase preparation burden. The commercial case is strongest in markets where cold-chain reliability is weak or where vial waste is significant.

How strong is the Nivestym patent estate?

The Nivestym patent estate is strategically stronger in manufacturing and presentation than in basic excipient composition.

Patent area	Relative commercial strength	Principal issue
Basic filgrastim composition	Low to moderate	Mature technology and prior art
Sorbitol-acetate-polysorbate formulation	Low to moderate	Established excipient use
Specific stability ranges	Moderate	Requires reproducible technical effect
Manufacturing process	Moderate to strong	Process details can be difficult to design around
Prefilled syringe and device	Moderate	Device claims may create narrow barriers
High-concentration formulation	Moderate	Clinical, stability, and device evidence required
Cold-chain excursion formulation	Moderate	Value depends on validated label advantage
Supply and quality systems	Strong operationally	Not necessarily enforceable as a patent

A credible patent program should emphasize narrow, data-backed claims. Formulation claims should tie the excipient combination to measurable outcomes such as reduced high-molecular-weight species, lower particle burden, longer stability, or improved container compatibility.

How does Nivestym compare with Zarxio and Neupogen?

Product	Sponsor	Product type	U.S. approval status	Commercial position
Neupogen	Amgen	Reference filgrastim	Original biologic	Established reference product
Zarxio	Sandoz	Filgrastim biosimilar	Approved 2015	First U.S. filgrastim biosimilar
Nivestym	Pfizer	Filgrastim-aafi biosimilar	Approved 2018	Large-scale sponsor and contracting platform
Releuko	Lupin/Visu?	Filgrastim biosimilar	Approved 2022	Additional U.S. competition

Nivestym competes primarily on net price, supply assurance, institutional contracting, specialty-distributor access, and payer acceptance. Excipient differences are unlikely to drive routine hospital purchasing unless they affect stability, storage, administration, or device performance.

What is the FDA regulatory status of Nivestym?

Nivestym is FDA-approved as a biosimilar to Neupogen for indications including:

• Cancer patients receiving myelosuppressive chemotherapy.
• Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy.
• Cancer patients undergoing myeloablative chemotherapy followed by bone marrow transplantation.
• Patients undergoing autologous peripheral blood progenitor-cell collection and therapy.
• Patients with severe chronic neutropenia.

The approved label specifies administration by subcutaneous or intravenous routes depending on the indication. It also includes warnings relating to splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle-cell disorders, and glomerulonephritis [1].

Nivestym approval does not automatically establish interchangeable status. Interchangeability can affect pharmacy substitution and payer utilization, but it requires a separate FDA determination supported by the applicable switching evidence and regulatory requirements.

What licensing deals and commercial partnerships affect Nivestym?

Nivestym is a Pfizer product. Its commercial opportunity is linked to Pfizer’s biologics manufacturing, distribution, hospital contracting, and biosimilar commercialization capabilities. Public disclosures do not provide a separately reported Nivestym revenue line, so product-specific revenue exposure cannot be calculated reliably from Pfizer’s financial reporting.

For potential partners, the more realistic opportunity areas are:

• Regional commercialization in markets without strong filgrastim biosimilar access.
• Hospital and oncology-clinic distribution.
• Prefilled syringe or autoinjector technology.
• Excipient raw-material supply with enhanced quality specifications.
• Cold-chain packaging and temperature-monitoring systems.
• Contract manufacturing for selected geographic markets.
• Formulation technology licensed for a follow-on filgrastim product.

A licensing strategy based only on common excipients is unlikely to command strong exclusivity. A package combining formulation data, device rights, manufacturing know-how, and regulatory support has greater commercial value.

What generic and biosimilar launch risks exist for Nivestym?

The principal risks are biosimilar competition, price compression, tender losses, manufacturing interruptions, and payer preference for interchangeable products.

Near-term launch scenario

A new filgrastim biosimilar could enter with a lower net price and compete for hospital tenders. The entrant would not need to reproduce Nivestym’s excipients if its product demonstrates biosimilarity to Neupogen.

Differentiated formulation scenario

A competitor could use a different surfactant, concentration, or container system. The product would need to show comparable quality, clinical performance, and immunogenicity. The development cycle would be longer, but the sponsor could seek a defensible device or formulation position.

Supply-constrained scenario

Manufacturing reliability could be more important than list price during shortages. A supplier with redundant production, validated cold-chain packaging, and consistent fill-finish capacity could win share even without a novel formulation.

Key Takeaways

• Nivestym uses a conventional filgrastim formulation based on acetate buffering, sorbitol, polysorbate 80, and water for injection.
• The strongest excipient opportunities are improved polysorbate control, lower particle formation, temperature-excursion resistance, and compatibility with next-generation delivery devices.
• Broad patents on filgrastim with common excipients are likely to face substantial prior-art challenges.
• Nivestym is a Purple Book biosimilar, not a conventional Orange Book product.
• Paragraph IV is not the primary patent pathway; BPCIA procedures and federal patent litigation are more relevant.
• Pfizer does not publicly report Nivestym revenue as a separate product line.
• Commercial differentiation is more likely to come from supply, contracting, device design, and validated stability than from a basic excipient substitution.
• A new formulation would require FDA comparability, stability, container-closure, and potentially combination-product evidence.

FAQs About Nivestym Excipient and Commercial Strategy

Can Nivestym be reformulated with polysorbate 20 instead of polysorbate 80?

Yes, technically, but the change would require extensive comparability, stability, aggregation, particle, immunogenicity, and container-compatibility data. It would be a product-development project rather than a routine manufacturing change.

Does Nivestym have a patent on its excipient combination?

A specific formulation patent may exist in a relevant jurisdiction, but the use of sorbitol, acetate, and polysorbate 80 with recombinant filgrastim is not, by itself, a strong basis for broad exclusivity. Enforceability would depend on claim scope, priority dates, prosecution history, validity, and demonstrated technical effects.

Would an autoinjector create new exclusivity for Nivestym?

An autoinjector could support device, combination-product, or use claims. It would not automatically create broad exclusivity over filgrastim. The commercial protection would depend on the device claims and whether competitors could use an alternative delivery system.

Is Nivestym interchangeable with Neupogen?

Nivestym is FDA-approved as a biosimilar to Neupogen. Biosimilarity and interchangeability are distinct regulatory concepts. Automatic pharmacy substitution depends on an FDA interchangeability designation and applicable state law.

What is the best commercial excipient opportunity for a follow-on filgrastim product?

The strongest opportunity is a formulation that combines low particulate burden, improved surfactant stability, validated temperature-excursion tolerance, and a user-friendly prefilled or autoinjector presentation. A single common-excipient substitution is less likely to create durable commercial differentiation.

References

1. U.S. Food and Drug Administration. (2018). Nivestym (filgrastim-aafi) injection, prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. U.S. Food and Drug Administration. (2020). Questions and answers on biosimilar development and the BPCI Act. https://www.fda.gov/

4. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119.